Cannabinoids Showed Opioid-Sparing Potential in Animal Studies but Not in Human Trials
A comprehensive meta-analysis found that cannabinoids reduced the effective morphine dose by 3.5x in animal studies, but randomized human trials found no significant opioid-sparing effect for any pain type.
Quick Facts
What This Study Found
Preclinical meta-analysis showed THC reduced the effective morphine dose by 3.5-fold (95% CI 2.04-6.03). However, meta-analysis of human RCTs in cancer pain found no effect on opioid dose (mean difference -3.8 mg, 95% CI -10.97 to 3.37) and more adverse events with cannabinoids (RR 1.13).
Key Numbers
Preclinical: morphine ED50 was 3.5x lower with THC (95% CI 2.04-6.03). Cancer pain RCTs (4 studies): no effect on opioid dose (mean diff -3.8 mg). Adverse events higher with cannabinoids (RR 1.13, 95% CI 1.03-1.24). Observational studies: 39% reported opioid cessation, 85% reported reduction. 15 ongoing trials identified.
How They Did This
Systematic review and meta-analysis of 92 studies (from 2016 onwards) including preclinical studies, healthy volunteer experiments, and clinical trials across acute pain, cancer pain, and chronic non-cancer pain. Searched Scopus, Cochrane, Medline, and Embase.
Why This Research Matters
The idea that cannabis could reduce opioid needs during the opioid crisis has enormous appeal. This review reveals a striking disconnect between promising animal data and disappointing human trial results, which is important for setting realistic expectations.
The Bigger Picture
The gap between observational studies (where patients report opioid reduction) and RCTs (where no reduction is found) is a recurring pattern in cannabis research. This may reflect placebo effects, selection bias, or the possibility that specific subgroups benefit while others do not.
What This Study Doesn't Tell Us
The review included studies from 2016 onwards only (updating a prior review). RCTs were small and used different cannabinoid preparations. Observational studies had high heterogeneity (I2 >90%). The variety of pain conditions makes pooling difficult.
Questions This Raises
- ?Why do observational studies and RCTs reach opposite conclusions?
- ?Are specific cannabinoid formulations or patient populations more likely to show opioid-sparing effects?
- ?Will the 15 ongoing trials shift the evidence?
Trust & Context
- Key Stat:
- 3.5x lower morphine dose with THC in animals, but 0 mg difference in human RCTs
- Evidence Grade:
- Strong: comprehensive systematic review and meta-analysis of 92 studies across multiple study designs and pain types.
- Study Age:
- Published in 2022, updating a prior review with studies from 2016 onwards.
- Original Title:
- Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies.
- Published In:
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 47(7), 1315-1330 (2022)
- Authors:
- Nielsen, Suzanne(6), Picco, Louisa, Murnion, Bridin(4), Winters, Bryony, Matheson, Justin, Graham, Myfanwy, Campbell, Gabrielle, Parvaresh, Laila, Khor, Kok-Eng, Betz-Stablein, Brigid, Farrell, Michael, Lintzeris, Nicholas, Le Foll, Bernard
- Database ID:
- RTHC-04104
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
Should people use cannabis to reduce their opioid medications?
The highest-quality human evidence (randomized trials) did not find that cannabinoids reduced opioid needs. While many patients in surveys report reducing opioids after starting cannabis, this has not been confirmed in controlled settings.
Why do animal studies show benefit but human studies do not?
Animal studies use controlled doses and standardized pain models. Human pain is more complex, and RCTs involve different cannabinoid products, doses, and patient populations. The translation gap is a known challenge in pain research.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04104APA
Nielsen, Suzanne; Picco, Louisa; Murnion, Bridin; Winters, Bryony; Matheson, Justin; Graham, Myfanwy; Campbell, Gabrielle; Parvaresh, Laila; Khor, Kok-Eng; Betz-Stablein, Brigid; Farrell, Michael; Lintzeris, Nicholas; Le Foll, Bernard. (2022). Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 47(7), 1315-1330. https://doi.org/10.1038/s41386-022-01322-4
MLA
Nielsen, Suzanne, et al. "Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies.." Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2022. https://doi.org/10.1038/s41386-022-01322-4
RethinkTHC
RethinkTHC Research Database. "Opioid-sparing effect of cannabinoids for analgesia: an upda..." RTHC-04104. Retrieved from https://rethinkthc.com/research/nielsen-2022-opioidsparing-effect-of-cannabinoids
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.